Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI‐PIO) in chronic myeloid leukemia with deep molecular response
Pagnano, Katia B.B., Lopes, Ana Beatriz P., Miranda, Eliana C., Delamain, Márcia T., Duarte, Gislaine O., Rodrigues, Bruna R.V., Povoa, Valquiria M.O., Furlin, Graziele C.P., Vianna, Jessica C., Silva, Matheus A.S., De Souza, Carmino A, De Paula, Erich V
Published in American journal of hematology (01.12.2020)
Published in American journal of hematology (01.12.2020)
Get full text
Journal Article
B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line
Da Silva, Matheus Sebastian, Miranda, Eliana C, Delamain, Marcia Torresan, Duarte, Gislaine Oliveira, Vergilio, Bruna R, Lopes, Ana Beatriz Pascoal, Vianna, Jessica CN, De Souza, Carmino Antonio, De Paula, Erich Vinicius, Pagnano, Katia B
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article
Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials
Pagnano, Katia B, Seguro, Fernanda S, Miranda, Eliana C, Lopes, Ana Beatriz Pascoal, Abdo, Andre, Delamain, Marcia Torresan, Pereira, Thales, Duarte, Gislaine Borba, Santos, Fernanda Maria, Vianna, Jessica CN, Da Silva, Matheus Sebastian, Nardinelli, Luciana, Povoa, Valquiria, Pavan, Graziele, Vergilio, Bruna R, Rocha, Vanderson, Souza, Carmino Antonio, De Paula, Erich V, Bendit, Israel
Published in Blood (13.11.2019)
Published in Blood (13.11.2019)
Get full text
Journal Article